Journal of Clinical Lipidology
Volume 4, Issue 3 , Pages 198-199 , May 2010

Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia

  • Image Result

    Serum phosphorus concentrations by treatment group at baseline (week 0), and weeks 4, 8, 12, 18, 24, 30, and 36, among those with a baseline serum phosphorus of >3.5 mg/dL. ERN-L, extended-release nia

    Serum phosphorus concentrations by treatment group at baseline (week 0), and weeks 4, 8, 12, 18, 24, 30, and 36, among those with a baseline serum phosphorus of >3.5 mg/dL. ERN-L, extended-release niacin + laropiprant.

PII: S1933-2874(10)00108-X

doi: 10.1016/j.jacl.2010.03.009

Journal of Clinical Lipidology
Volume 4, Issue 3 , Pages 198-199 , May 2010

Article Tools

* Image Usage & Resolution